Outlook Therapeutics, Inc. 8-K

What Happened
Outlook Therapeutics, Inc. (OTLK) announced in an 8-K filed April 7, 2026 that it submitted a Formal Dispute Resolution Request (FDRR) to the U.S. Food and Drug Administration (FDA). The FDRR follows a recent Type A meeting about the December 30, 2025 Complete Response Letter (CRL) for the company’s Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab) to treat neovascular age-related macular degeneration. The FDA has accepted the FDRR and granted a meeting with the deciding official to be conducted in April 2026. A press release dated April 7, 2026 was attached to the filing.

Key Details

• Filing date: Current Report on Form 8-K filed April 7, 2026.
• Regulatory context: CRL issued on December 30, 2025 for the BLA for ONS-5010/LYTENAVA (bevacizumab).
• Action taken: Company submitted an FDRR; FDA accepted the FDRR and scheduled a meeting with the deciding official for April 2026.
• Press release: Company’s April 7, 2026 press release is included as Exhibit 99.1 to the 8-K.

Why It Matters
This filing notifies investors that Outlook has taken a formal regulatory step to dispute and seek resolution of the FDA’s December 2025 CRL for its ocular bevacizumab product. Acceptance of the FDRR and a scheduled deciding-official meeting are procedural milestones in the FDA review process that may influence the timing and path forward for the BLA for ONS-5010/LYTENAVA. Investors follow these steps because they relate directly to potential approval timelines and commercialization prospects for the company’s lead product.